Tissue concentrations of prothymosin alpha: a novel proliferation index of primary breast cancer.
Dominguez. F F; Magdalena. C C; Cancio. E E; Roson. E E; Paredes. J J; Loidi. L L; Zalvide. J J; Fraga. M M; Forteza. J J; Regueiro. B J BJ
Key Findings
- Prothymosin‑alpha (detected as thymosin‑alpha‑1) levels are significantly elevated in invasive ductal carcinoma compared to normal breast tissue.
- Higher PT‑alpha levels correlate with a greater number of positive axillary lymph nodes (rs = 0.5384, p < 0.01).
- Elevated PT‑alpha is associated with a higher percentage of tumor cells in the S or G2/M phases (rs = 0.5027, p < 0.01).
- All patients who later developed distant metastases had tumor PT‑alpha levels above 124 ng thymosin‑alpha‑1 per mg protein.
Practical Outcomes
- The study identifies PT‑alpha as a potential prognostic marker for aggressive breast cancer, but it offers no guidance on supplementation, dosing, or lifestyle interventions. For biohackers focused on longevity or performance, the findings are not directly actionable or relevant to everyday protocols.
Summary
Researchers measured a protein fragment called thymosin‑alpha‑1 (part of prothymosin‑alpha) in breast cancer tissue and found it was much higher than in normal breast tissue. Higher levels were linked to more lymph‑node spread, faster‑growing tumor cells, and later development of distant metastases.
Abstract
In 71 patients with classic invasive ductal carcinomas, levels of prothymosin alpha (PT alpha), as assayed by a radioimmunoassay that detects thymosin alpha 1 (the NH2-terminal fragment of PT alpha), were significantly greater in tumour samples than in normal breast tissue. PT alpha levels were correlated with (a) the number of positive axillary lymph nodes (rs = 0.5384, P < 0.01), and (b) the percentage of tumour cells in the S or G2/M phase as assessed by flow cytometry (rs = 0.5027, P < 0.01). Since the beginning of this study in 1989, 21 patients have presented distant metastases, all of whom were previously shown to have tumour PT alpha levels greater than 124 ng of thymosin alpha 1/mg protein. The present report indicates that PT alpha might be used to identify breast cancer patients at high risk for distant metastases.
Study Information
pubmed
1993
10.1016/s0959-8049(05)80433-2